Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EBT: 2021-2025

Historic EBT for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -$1.7 million.

  • InMed Pharmaceuticals' EBT fell 2.92% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.2 million, marking a year-over-year decrease of 20.58%. This contributed to the annual value of -$8.2 million for FY2025, which is 6.44% down from last year.
  • InMed Pharmaceuticals' EBT amounted to -$1.7 million in Q3 2025, which was up 3.43% from -$1.8 million recorded in Q2 2025.
  • InMed Pharmaceuticals' EBT's 5-year high stood at -$336,591 during Q2 2023, with a 5-year trough of -$7.9 million in Q2 2022.
  • Over the past 3 years, InMed Pharmaceuticals' median EBT value was -$1.8 million (recorded in 2025), while the average stood at -$1.8 million.
  • Its EBT has fluctuated over the past 5 years, first skyrocketed by 95.72% in 2023, then plummeted by 473.57% in 2024.
  • Quarterly analysis of 5 years shows InMed Pharmaceuticals' EBT stood at -$4.3 million in 2021, then soared by 51.01% to -$2.1 million in 2022, then increased by 29.55% to -$1.5 million in 2023, then slumped by 74.20% to -$2.6 million in 2024, then decreased by 2.92% to -$1.7 million in 2025.
  • Its last three reported values are -$1.7 million in Q3 2025, -$1.8 million for Q2 2025, and -$2.1 million during Q1 2025.